›› 2020, Vol. 40 ›› Issue (1): 128-.doi: 10.3969/j.issn.1674-8115.2020.01.021

• Review • Previous Articles     Next Articles

Clinical application of PD-1/PD-L1 to prognosis prediction and treatment of triple-negative breast cancer

ZHANG Feng-chun, ZHANG Shuo-yuan, CHEN Tian-en, XU Ying-chun   

  1. 1. Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021, China; 2. Department of Oncology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 3. Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
  • Online:2020-01-28 Published:2020-03-05
  • Supported by:
    National Natural Science Foundation of China (81301858); Natural Science Foundation of Jiangsu Project (BK20181186).

Abstract: Programmed death-1 (PD-1) receptor and programmed death-ligand 1 (PD-L1) as a pair of T cell immune response co-stimulatory molecules play a negative role in adoptive immunityinhibiting T lymphocyte function. Blocking the PD-1/PD-L1 signaling pathway has been a hot spot of research and treatment of cancer. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and there is no approved targeted therapy. Immunotherapy representedPD-1/PD-L1 blockers, is getting widely studied due to the medical potential of therapy for TNBC. Thereinto, the clinical researches of the monoclonal antibodies against PD-1 or PD-L1 have brought a promising future for the treatment of metastatic TNBC. Currently, there are several trials with anti-PD-1 or anti-PD-L1 monoclonal antibodies and their combination with other therapies in salvage, neoadjuvant, and adjuvant settings on going. In this article, the authors review the current studies about potential value of PD-1/PD-L1 in prognosis, prediction, and treatment in TNBC, intending to cast insight on future basic and clinical studies.

Key words: programmed death-1/programmed death-ligand 1 (PD-1/PD-L1), triple-negative breast cancer, treatment, prognosis